Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 218

1.

Would young women attending sexually transmitted disease clinics benefit from human papillomavirus vaccination? An assessment of human papillomavirus DNA and seropositivity from human papillomavirus sentinel surveillance, 2003-2005.

Dunne EF, Flagg EW, Unger ER, Hsu K, Ghanen K, Kerndt P, Shlay JC, Koutsky LA, Datta DS, Panicker G, Zaidi A, Weinstock H, Markowitz LE.

Sex Transm Dis. 2014 Jan;41(1):46-9. doi: 10.1097/OLQ.0000000000000071.

PMID:
24326582
2.

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.

Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.

J Natl Cancer Inst. 2010 Mar 3;102(5):325-39. doi: 10.1093/jnci/djp534. Epub 2010 Feb 5.

PMID:
20139221
3.

Spectrum of genital human papillomavirus infection in a female adolescent population.

Jamison JH, Kaplan DW, Hamman R, Eagar R, Beach R, Douglas JM Jr.

Sex Transm Dis. 1995 Jul-Aug;22(4):236-43.

PMID:
7482107
4.

Human papillomavirus vaccination and cervical cytology in young minority women.

Brogly SB, Perkins RB, Zepf D, Longtine J, Yang S.

Sex Transm Dis. 2014 Aug;41(8):511-4. doi: 10.1097/OLQ.0000000000000162.

PMID:
25013981
5.

Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection.

FUTURE II Study Group..

J Infect Dis. 2007 Nov 15;196(10):1438-46. Epub 2007 Oct 31.

PMID:
18008221
6.

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, De Carvalho NS, Germar MJ, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G; HPV PATRICIA Study Group..

Lancet Oncol. 2012 Jan;13(1):89-99. doi: 10.1016/S1470-2045(11)70286-8. Epub 2011 Nov 8. Erratum in: Lancet Oncol. 2012 Jan;13(1):e1.

PMID:
22075171
7.

Prevalence and type distribution of human papillomavirus in healthy Japanese women aged 20 to 25 years old enrolled in a clinical study.

Konno R, Tamura S, Dobbelaere K, Yoshikawa H.

Cancer Sci. 2011 Apr;102(4):877-82. doi: 10.1111/j.1349-7006.2011.01878.x. Epub 2011 Feb 17.

8.

A controlled trial of a human papillomavirus type 16 vaccine.

Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU; Proof of Principle Study Investigators..

N Engl J Med. 2002 Nov 21;347(21):1645-51.

9.

[Acceptability of vaccination against human papillomavirus (HPV) by pediatricians, mothers and young women in Ho Chi Minh City, Vietnam].

Phan DP, Pham QT, Strobel M, Tran DS, Tran TL, Buisson Y.

Rev Epidemiol Sante Publique. 2012 Dec;60(6):437-46. doi: 10.1016/j.respe.2012.03.010. Epub 2012 Nov 6. French.

PMID:
23137871
10.

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.

de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menéndez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C, Ordi J, Andújar M, Castellsagué X, Sánchez GI, Nowakowski AM, Bornstein J, Muñoz N, Bosch FX; Retrospective International Survey and HPV Time Trends Study Group..

Lancet Oncol. 2010 Nov;11(11):1048-56. doi: 10.1016/S1470-2045(10)70230-8. Epub 2010 Oct 15.

PMID:
20952254
11.

Prevalence of human papillomavirus among STD clinic attenders in Jamaica: association of younger age and increased sexual activity.

Figueroa JP, Ward E, Luthi TE, Vermund SH, Brathwaite AR, Burk RD.

Sex Transm Dis. 1995 Mar-Apr;22(2):114-8.

PMID:
7624812
12.

Human Pappilomavirus (HPV) induced cancers and prevention by immunization.

Khaliq SA, Shyum Naqvi SB, Fatima A.

Pak J Pharm Sci. 2012 Oct;25(4):763-72.

PMID:
23009992
13.

Why consider human papillomavirus vaccination in older women?

Poppe WA, Simon PH, De Ridder MR.

Gynecol Obstet Invest. 2010;70(4):237-43. doi: 10.1159/000314012. Epub 2010 Oct 16.

PMID:
21051842
14.

Knowledge of cervix cancer, human papilloma virus (HPV) and HPV vaccination at the moment of introduction of the vaccine in women in Belgium.

Donders GG, Gabrovska M, Bellen G, Van Keirsbilck J, Van Den Bosch T, Riphagen I, Verjans M.

Arch Gynecol Obstet. 2008 Apr;277(4):291-8. Epub 2007 Oct 27.

PMID:
17965870
15.

[Cervical cancer prevention: the impact of HPV vaccination].

Monsonégo J.

Gynecol Obstet Fertil. 2006 Mar;34(3):189-201. Epub 2006 Mar 10. Review. French.

PMID:
16529969
16.

Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data.

Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, Wand H, Fairley CK.

Lancet Infect Dis. 2011 Jan;11(1):39-44. doi: 10.1016/S1473-3099(10)70225-5. Epub 2010 Nov 8.

PMID:
21067976
17.

Uptake of the HPV vaccination programme in England: a cross-sectional survey of young women attending sexual health services.

Sacks RJ, Copas AJ, Wilkinson DM, Robinson AJ.

Sex Transm Infect. 2014 Jun;90(4):315-21. doi: 10.1136/sextrans-2013-051179. Epub 2014 Mar 17.

PMID:
24636998
18.

HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.

Castellsagué X, Schneider A, Kaufmann AM, Bosch FX.

Gynecol Oncol. 2009 Dec;115(3 Suppl):S15-23. doi: 10.1016/j.ygyno.2009.09.021. Epub 2009 Oct 12.

PMID:
19819540
19.

The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening.

Sigurdsson K, Sigvaldason H, Gudmundsdottir T, Sigurdsson R, Briem H.

Acta Obstet Gynecol Scand. 2009;88(1):27-35. doi: 10.1080/00016340802566770.

PMID:
19031282
20.

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmerón J, Chow SN, Apter D, Kitchener H, Teixeira JC, Skinner SR, Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Harper DM, Huh W, Hardt K, Zahaf T, Descamps D, Struyf F, Dubin G, Lehtinen M; HPV PATRICIA Study Group..

Lancet Oncol. 2012 Jan;13(1):100-10. doi: 10.1016/S1470-2045(11)70287-X. Epub 2011 Nov 8. Erratum in: Lancet Oncol. 2012 Jan;13(1):e1.

PMID:
22075170

Supplemental Content

Support Center